TG Therapeutics Reports BRIUMVI Data From ENHANCE Phase 3b …
WEB3 days ago · Sep. 18, 2024, 08:24 AM. (RTTNews) - TG Therapeutics (TGTX) presented updated data from the ENHANCE Phase 3b trial evaluating BRIUMVI in patients with relapsing forms of multiple sclerosis. The ...
Home - TG Therapeutics
WEBLATEST NEWS New BRIUMVI® (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis
New Data for BRIUMVI® (ublituximab-xiiy) Demonstrate that 92
WEB4 days ago · NEW YORK, Sept. 18, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced updated data presentations including new five-year data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI ® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 European Committee for Treatment and ...
TG Therapeutics - New BRIUMVI Data from the ENHANCE Phase …
WEB2 days ago · NEW YORK - TG Therapeutics, Inc. (NASDAQ: TGTX), today presented updated data from the ENHANCE Phase 3b trial evaluating BRIUMVI (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting.. Michael S. Weiss, the Company's Chairman and Chief Executive Officer stated ...
Press Releases - TG Therapeutics, Inc.
WEBJun 3, 2024 · NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming presentations highlighting study designs for post-marketing studies being undertaken for BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis
TG Therapeutics Reports BRIUMVI Data From ENHANCE Phase 3b …
WEB3 days ago · TG Therapeutics presented updated data from the ENHANCE Phase 3b trial evaluating BRIUMVI in patients with relapsing forms of multiple sclerosis.The company said the data showed rapid 30 minute infusions were well tolerated. Data also showed that patients switching from prior anti-CD20 treatment …
TG Therapeutics Stock Surges After Preventing MS Relapses Over …
WEB3 days ago · Related news TG Therapeutics Receives Composite Rating Upgrade. 9/09/2024 TG Therapeutics saw an improvement in its IBD SmartSelect Composite Rating Tuesday, from 94 to 97.. 9/09/2024 TG ...
TG Therapeutics, Inc. (TGTX) Stock Price, News, Quote
WEBFind the latest TG Therapeutics, Inc. (TGTX) stock quote, history, news and other vital information to help you with your stock trading and investing.
Are Robust Financials Driving The Recent Rally In TG Therapeutics…
WEB2 days ago · Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity. So, based on the above formula, the ROE for TG Therapeutics is: 54% = US$96m ÷ US$178m (Based on the trailing ...
New BRIUMVI® (ublituximab-xiiy) Data from the ENHANCE Phase …
WEB4 days ago · TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has received U.S. Food and Drug Administration (FDA) approval for BRIUMVI ...